Sevelamer hydrochloride with or without alphacalcidol or higher dialysate calcium vs calcium carbonate in dialysis patients: An open-label, randomized study

Nephrology Dialysis Transplantation

Volumn 18, Issue 3, 2003, Pages 582-589

  Sadek, Tarek ^a   Mazouz, Hakim ^a   Bahloul, Hedi ^a   Oprisiu, Roxana ^a   El Esper, Najeh ^a   El Esper, Isabelle ^a   Boitte, Francis ^a   Brazier, Michel ^a   Moriniere, Philippe ^a   Fournier, Albert ^a  

^a AMIENS UNIVERSITY HOSPITAL   (France)

Author keywords

25 OH vitamin D; Bicarbonate; Calcium carbonate; LDL cholesterol; Parathyroid hormone; Sevelamer hydrochloride

Indexed keywords

25 HYDROXYVITAMIN D; ALFACALCIDOL; BICARBONATE; CALCITRIOL; CALCIUM CARBONATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PARATHYROID HORMONE; PHOSPHATE; PLASMA PROTEIN; SEVELAMER;

ARTERY CALCIFICATION; ARTICLE; BICARBONATE BLOOD LEVEL; CALCIUM BALANCE; CALCIUM BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIALYSATE; DRUG DOSE REGIMEN; DRUG EFFICACY; DYSLIPIDEMIA; HEMODIALYSIS PATIENT; HUMAN; HYPERCALCEMIA; HYPERPARATHYROIDISM; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY;

ADJUVANTS, IMMUNOLOGIC; ANTACIDS; CALCIUM; CALCIUM CARBONATE; DIALYSIS SOLUTIONS; DRUG THERAPY, COMBINATION; EPOXY COMPOUNDS; FOLLOW-UP STUDIES; HUMANS; HYDROXYCHOLECALCIFEROLS; HYPERCALCEMIA; HYPERPARATHYROIDISM; KIDNEY FAILURE, CHRONIC; POLYAMINES; POLYETHYLENES; RENAL DIALYSIS; TIME FACTORS;

EID: 0037342637     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/18.3.582     Document Type: Article

References (20)

1. Chertow GW, Burke SK, Dillon MA, Slatopolsky E, for the Renagel Study Group. Long-term effects of sevelamer hydrochloride on the calcium phosphate product and lipid profile on haemodialysis patients. Nephrol Dial Transplant 1999; 14: 2907-2914
2. Moriniere P, Fournier A, Leflon A et al. Comparison of 1α OH vitamin D3 and high doses of calcium carbonate for the control of hyperparathyroidism and hyperaluminemia in patients on maintenance dialysis. Nephron 1985; 39: 309-315
3. Indridason OS, Quarles ED. Comparison of treatments for mild secondary hyperparathyroidism, in hemodialysis patients. Durham Renal Osteodystrophy Study Group. Kidney Int 2000; 57: 282-292
4. Coburn JW. Use of oral and parenteral calcitriol in the treatment of renal osteodystrophy. Kidney Int 1990; 38 [Suppl 29]: S54-S61
5. Liu S, Chu H. Studies of calcium and phosphorus metabolism with special reference to pathogenesis and effects of dihydrotachysterol and iron. Medicine 1943; 22: 103-161
6. Bleyer AJ, Burke SK, Dillon M et al. A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients. Am J Kidney Dis 1999; 33: 694-701
7. Chertow GM, Dillon M, Burke SK et al. A randomized trial of sevelamer hydrochloride (Renagel) with and without supplemental calcium. Strategies for the control of hyperphosphatemia and hyperparathyroidism in hemodialysis patients. Clin Nephrol 1999; 51: 18-26
8. Ben Hamida F, El Esper I, Compagnon M, Moriniere P, Fournier A. Long-term (6 months) cross-over comparison of calcium acetate with calcium carbonate as phosphate binder. Nephron 1993; 63: 258-262
9. Renaud H, Atik A, Herve M et al. Evaluation of vascular calcinosis risk factors in patients on chronic hemodialysis: lack of influence of calcium carbonate. Nephron 1988; 48: 28-32
10. Goldsmith DJ, Covic A, Sambrook PA, Ackrill P. Vascular calcification in long-term haemodialysis patients in a single unit: a retrospective analysis. Nephron 1997; 77: 37-43
11. Chertow GM, Burke SK, Raggi P, for the Treat to Goal Working Group. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002; 62: 245-252
12. Fournier A, Morinière P, Ben Hamida F, El Esper N. Use of alkaline calcium salts as phosphate binder in uremic patients. Kidney Int 1992; 42 [Suppl 38]: S50-S61
13. Fournier A, Chertow GM. Sevelamer, Ca x P product and vitamin D. Nephrol Dial Transplant 2001; 16: 429-430
14. Fournier AE, Arnaud CD, Johnson WJ, Taylor WF, Goldsmith RS. Etiology of hyperparathyroidism and bone disease during chronic hemodialysis. I. Association of bone disease with potentially etiologic factors; II. Factors affecting serum immunoreactive parathyroid hormone. J Clin Invest 1971; 50: 592-605
15. Ghazali A, Fardellone P, Pruna A et al. Is a low plasma 25-(OH) vitamin D a major risk factor for hyperparathyroidism and Looser's zones independent of calcitriol? Kidney Int 1999; 55: 2169-2177
16. Gallieni M, Cozzolino M, Brancaccio D. Transient decrease of serum bicarbonate levels with sevelamer hydrochloride as the phosphate binder. Kidney Int 2000; 57: 1776-1777
17. Bonifacio D, Malineni K, Kadakia RA, Soman SS, Sandberg KR, McCullough PA. Coronary calcification and cardiac events after percutaneous intervention in dialysis patients. J Cardiovasc Risk 2001; 8: 133-137
18. Heart Protection Study Collaborative group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22
19. Sarnak MJ, Levey AS. Cardiovascular disease and chronic renal disease: a new paradigm. Am J Kidney Dis 2000; 35: S117-S131
20. Schömig M, Ritz E. Management of disturbed calcium metabolism in uremic patients: use of vitamin D metabolites. Nephrol Dial Transplant 2000; 15: 18-24